The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 7 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for BioLife Solutions, Inc. is $31.00, about 8.3% below its August 5 closing price of $33.80
The stock recently traded at 129 times the next 12-month earnings vs. a P/E of 86 three months ago
Q2 revenue and margin
US cell processing tools maker's Q2 revenue rose 21% yr/yr to $28.5 mln
Q2 adjusted gross margin was 65%, down from 66% a year ago
Biopreservation media — Co attributed Q2 revenue growth to strong performance of its biopreservation media franchise, per CEO Roderick de Greef
Clinical trial adoption — Biopreservation media used in about 250 ongoing US clinical trials, representing over 70% market share, including more than 30 Phase III trials
Commercial therapy embeddedness — Biopreservation media embedded in 18 unique commercial CGTs as of June 30, with expectations for further product approvals and geographic expansion
BLFS•
